We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Galectin Therapeutics Inc | NASDAQ:GALT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.09 | -3.59% | 2.42 | 1.75 | 2.75 | 2.615 | 2.395 | 2.51 | 159,789 | 01:00:00 |
|
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading
Symbol
|
Name of each exchange on which
registered
|
|
|
|
Item 5.07 |
Submission of Matters to a Vote of Security Holders.
|
Name
|
Votes For
|
Votes Withheld
|
Broker Non-Votes
|
|
Gilbert F. Amelio, Ph.D.
|
24,856,340
|
1,155,282
|
18,910,166
|
|
Benjamin S. Carson, Sr., M.D.
|
25,523,084
|
488,538
|
18,910,166
|
|
Kary Eldred
|
25,603,577
|
408,045
|
18,910,166
|
|
Kevin D. Freeman
|
24,969,444
|
1,042,178
|
18,910,166
|
|
Joel Lewis
|
25,560,738
|
450,884
|
18,910,166
|
|
Gilbert S. Omenn, M.D., Ph.D.
|
25,617,192
|
394,430
|
18,910,166
|
|
Marc Rubin, M.D.
|
25,016,122
|
995,500
|
18,910,166
|
|
Elissa J. Schwartz, Ph.D.
|
25,615,545
|
396,077
|
18,910,166
|
|
Harold H. Shlevin, Ph.D.
|
25,548,431
|
463,191
|
18,910,166
|
|
Richard E. Uihlein, Chairman
|
25,593,922
|
417,700
|
18,910,166
|
|
Richard A. Zordani
|
25,600,465
|
411,157
|
18,910,166
|
Votes For
|
Votes Against
|
Votes Abstain
|
44,481,830
|
252,254
|
187,704
|
Votes For
|
Votes Against
|
Votes Abstain
|
Broker Non-Votes
|
23,901,293
|
1,923,578
|
186,751
|
18,910,166
|
Galectin Therapeutics Inc. | |||
Date: December 11, 2023 |
By: | /s/ Jack W. Callicutt | |
Jack W. Callicutt | |||
Chief Financial Officer |
Document and Entity Information |
Dec. 07, 2023 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Dec. 07, 2023 |
Entity File Number | 001-31791 |
Entity Registrant Name | GALECTIN THERAPEUTICS INC |
Entity Central Index Key | 0001133416 |
Entity Incorporation, State or Country Code | NV |
Entity Tax Identification Number | 04-3562325 |
Entity Address, Address Line One | 4960 PEACHTREE INDUSTRIAL BOULEVARD |
Entity Address, Address Line Two | STE 240 |
Entity Address, City or Town | NORCROSS |
Entity Address, State or Province | GA |
Entity Address, Postal Zip Code | 30071 |
City Area Code | 678 |
Local Phone Number | 620-3186 |
Title of 12(b) Security | Common Stock $0.001 par value per share |
Trading Symbol | GALT |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
1 Year Galectin Therapeutics Chart |
1 Month Galectin Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions